About Open Access
An evaluation of 2-deoxy-2- [18F]fluoro-D-glucose and 3‟-Deoxy-3‟-[18F]-fluorothymidine uptake in human tumor xenograft models
Lookup NU author(s)
Professor Steve Wedge
Keen H, Pichler B, Kukuk D, Duchamp O, Raguin O, Shannon A, Whalley N, Jacobs V, Bales J, Gingles G, Ricketts S-A, Wedge SR
Molecular Imaging and Biology
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The aim of this study is to assess the variability of 2-deoxy-2-[18F]fluoro-d-glucose ([18F]-FDG) and 3′-deoxy-3′-[18F]-fluorothymidine ([18F]-FLT) uptake in pre-clinical tumor models and examine the relationship between imaging data and related histological biomarkers. Procedures: [18F]-FDG and [18F]-FLT studies were carried out in nine human tumor xenograft models in mice. A selection of the models underwent histological analysis for endpoints relevant to radiotracer uptake. Comparisons were made between in vitro uptake, in vivo imaging, and ex vivo histopathology data using quantitative and semi-quantitative analysis. Results: In vitro data revealed that [1-14C]-2-deoxy-d-glucose ([14C]-2DG) uptake in the tumor cell lines was variable. In vivo, [18F]-FDG and [18F]-FLT uptake was highly variable across tumor types and uptake of one tracer was not predictive for the other. [14C]-2DG uptake in vitro did not predict for [18F]-FDG uptake in vivo. [18F]-FDG SUV was inversely proportional to Ki67 and necrosis levels and positively correlated with HKI. [18F]-FLT uptake positively correlated with Ki67 and TK1. Conclusion: When evaluating imaging biomarkers in response to therapy, the choice of tumor model should take into account in vivo baseline radiotracer uptake, which can vary significantly between models.
Altmetrics provided by
Newcastle University Library, NE2 4HQ, United Kingdom. Tel: 0044 (191) 222 7657
©2016 Newcastle University Library